Enveric Biosciences Inc ENVB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ENVB is a good fit for your portfolio.
News
-
Enveric Biosciences Announces Preclinical Results Confirming Potential of EB-003 to be Dosed Orally
-
Aries Science & Technology and Enveric Biosciences Announce Licensing Agreement
-
Enveric Biosciences Announces Patent Granted for Drug Candidate
-
Enveric Biosciences Provides Strategic Outlook and Pipeline Update, Elevating EB-003 to Lead Development Candidate
-
Enveric Biosciences to Participate in BIO International Convention 2024
-
Enveric Biosciences Reports First Quarter 2024 Financial and Corporate Results
-
Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders
-
Enveric Biosciences Announces Signing of Non-Binding Term Sheet with Undisclosed Licensee for Exclusive License to Patented Methods of Treating Breast and Other Cancers Using Cannabinoids
Trading Information
- Previous Close Price
- $0.47
- Day Range
- $0.45–0.49
- 52-Week Range
- $0.41–3.90
- Bid/Ask
- $0.46 / $0.48
- Market Cap
- $3.74 Mil
- Volume/Avg
- 312,509 / 566,007
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. The company's lead program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. Enveric is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, being studied as a treatment of psychiatric disorders.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 26
- Website
- https://www.enveric.com
Valuation
|
Metric
|
ENVB
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.53 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
ENVB
Financial Strength
|
Metric
|
ENVB
|
|---|---|
Quick Ratio | 2.88 |
Current Ratio | 3.48 |
Interest Coverage | — |
Quick Ratio
ENVB
Profitability
|
Metric
|
ENVB
|
|---|---|
Return on Assets (Normalized) | −156.33% |
Return on Equity (Normalized) | −271.50% |
Return on Invested Capital (Normalized) | −261.04% |
Return on Assets
ENVB
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Xfjmltqmq | Lgbx | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Njcjkyts | Jvbfwz | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Drgkysnp | Yfhxhl | $118.7 Bil | |||
| Moderna Inc
MRNA
| Thpkncxgd | Ngpy | $46.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Brvwnmtm | Xgcmvt | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Gyfmylwq | Dmdd | $29.3 Bil | |||
| BioNTech SE ADR
BNTX
| Bjfdhlxw | Pqbrf | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Bsmmdgcn | Lvhrqq | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Fygqppptc | Kfkqs | $15.0 Bil | |||
| Incyte Corp
INCY
| Dwxwcykmt | Bvlhcc | $13.5 Bil |